Novartis hit by 2 late-stage trial failures

Good morning, healthcare professional.

Novartis faces mounting pressure after two critical late-stage programs failed within days, while the biotech sector sees contrasting fortunes with Ionis securing a breakthrough FDA approval. Meanwhile, a troubling gap between regulatory approval and patient access is leaving pancreatic cancer patients unable to obtain newly approved treatments despite FDA clearance.

These developments underscore the high-stakes nature of drug development, the persistent challenges in translating approvals into real-world access, and the ongoing volatility facing major pharmaceutical companies as they work to rebuild their pipelines. From clinical setbacks affecting entire drug classes to systemic healthcare delivery failures, today's news highlights both the promise and pitfalls of modern medicine.

In today's healthcare digest:

• Novartis reports failures in two pivotal late-stage trials
• Ionis gains FDA approval for rare Alexander disease treatment
• Pancreatic cancer patients struggle to access approved breakthrough drug
• BrainChild Bio secures $116M for pediatric brain cancer cell therapies

Novartis Suffers Double Setback with Two Late-Stage Drug Failures

Novartis reported failures in two critical late-stage programs within days, with neuromuscular drug del-desiran missing endpoints in myotonic dystrophy and cardiovascular therapy pelacarsen (partnered with Ionis) failing its pivotal trial. The pelacarsen failure raises broader questions about drugs targeting elevated lipoprotein(a) levels, a mechanism multiple companies have been pursuing.

Unpacked:

• Del-desiran failed to meet primary endpoints in the HARBOR trial for myotonic dystrophy type 1, adding pressure on Novartis as it rebuilds its pipeline.
• Pelacarsen's failure in the HORIZON cardiovascular outcomes study casts doubt on the therapeutic approach of targeting Lp(a) for heart disease prevention.
• These setbacks arrive at a challenging time for Novartis, which needs pipeline successes to offset patent expirations and maintain growth momentum.

Ionis Wins FDA Approval for Breakthrough Alexander Disease Treatment

Ionis Pharmaceuticals secured FDA approval for its rare neurology drug treating Alexander disease, marking a significant milestone characterized as a 'breakthrough' that establishes a key pillar of the company's commercial portfolio. Alexander disease is a rare and devastating neurological disorder with previously limited treatment options.

Unpacked:

• The approval provides Ionis with a commercial foundation in rare neurological diseases, diversifying its revenue sources beyond partnership royalties.
• Alexander disease affects the nervous system's white matter, causing developmental delays and neurological decline, making this approval particularly meaningful for patients.
• This success offers a positive counterbalance to Ionis following the pelacarsen failure with Novartis announced just days earlier.

Pancreatic Cancer Patients Face Access Barriers Despite FDA Drug Approval

Despite FDA approval of a breakthrough pancreatic cancer drug, patients are struggling to access the treatment due to administrative gaps between regulatory clearance and insurance coverage. The delay highlights systemic issues where approved therapies face reimbursement hurdles that prevent timely patient access.

Unpacked:

• Administrative processing delays between FDA approval and insurance coverage decisions are leaving pancreatic cancer patients unable to obtain newly available treatments.
• Pancreatic cancer has one of the poorest prognoses among cancers, making treatment delays particularly consequential for patient outcomes and survival.
• The gap exposes fundamental flaws in the U.S. healthcare system where regulatory approval doesn't guarantee practical availability or affordability.

BrainChild Raises $116M for Pediatric Brain Cancer Cell Therapies

BrainChild Bio secured $116 million in funding to advance cell therapy development for childhood brain cancers. The substantial financing will support CAR-T and other cell-based therapies specifically designed for pediatric brain tumor patients.

Unpacked:

• The $116 million round provides significant runway for BrainChild to advance multiple cell therapy programs through clinical development stages.
• Childhood brain cancers remain among the most challenging malignancies to treat, with limited effective therapies and poor survival rates.
• Cell therapy approaches represent a potentially transformative treatment modality that could address the unique biology of pediatric brain tumors.

The Shortlist

• AbbVie scored a win with its dual-acting myeloma drug etentamig in Phase 3 trials, helping the company catch up to rivals in the competitive multiple myeloma market.

• AstraZeneca posted strong late-stage results for experimental COPD treatment tozorakimab in the TITANIA and OBERON studies, showing reduced exacerbations.

• Inhibrx claimed the first clinical win for the long-sought OX40 immunotherapy target in HPV-positive head and neck cancer patients.

• Roivant announced its lung disease drug mosliciguat hit mid-stage study goals for pulmonary hypertension associated with interstitial lung disease.

• Novo Nordisk stopped two cardiovascular trials of inflammation-targeting drug ziltivekimab, though the company has not disclosed specific reasons for the decision.